The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2023 | Clinical outcomes of BTKi + Ven treatment in CLL/SLL: double-exposed vs double-refractory patients
Laura Samples, MD, University of Washington, Seattle, WA, shares insights from a study assessing clinical outcomes in patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) who were treated with both covalent BTK inhibitors (BTKi) and venetoclax (Ven). Highlighting the distinction between double-exposed and double-refractory patients, Dr Samples notes poorer overall survival (OS) and progression-free survival (PFS) outcomes in double-refractory patients. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
